In research literature, 5-Amino is generally treated as 5-amino-1-methylquinolinium (5-amino-1MQ), a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor used in one-carbon metabolism and epigenetic methylation research. 5-amino-1MQ competitively inhibits NNMT — an enzyme that converts nicotinamide (vitamin B3) to 1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. By blocking this reaction, 5-amino-1MQ increases the cellular SAM:SAH (S-adenosylhomocysteine) ratio, which enhances the methyl-donor capacity of the one-carbon pool available to histone and DNA methyltransferases. This shifts the epigenetic landscape toward increased H3K4me3 and H3K27me3 marks in cell models, linking NNMT inhibition to chromatin remodelling research. NNMT is overexpressed in multiple adipose tissue depots and certain cancer types, making it a target of interest in both metabolic and oncology research contexts.
Unlike the peptides in this catalogue, 5-amino-1MQ is a quinolinium small molecule — its research applications centre on enzyme inhibition biochemistry, one-carbon cycle flux analysis, and epigenomic profiling rather than receptor pharmacology. Isotope tracing experiments (¹³C-methionine or ²H-SAM) are frequently used alongside NNMT inhibitors to map methyl group flux quantitatively. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether 5-Amino behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.